The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Influence of age, sex and tumor type in the likelihood of inclusion in early clinical trials.
 
Maria Vieito
Consulting or Advisory Role - BMS GmbH & Co. KG; Roche
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Novartis (Inst); Roche/Genentech (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Travel, Accommodations, Expenses - Roche
Other Relationship - BMS GmbH & Co. KG (Inst); Debiopharm Group (Inst); HUTCHMED (Inst); Incyte (Inst); Mundipharma (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst); SERVIER (Inst); Taiho Oncology (Inst)
 
Katerin Ingrid Rojas
No Relationships to Disclose
 
Roger Berché
No Relationships to Disclose
 
Cristina Viaplana
No Relationships to Disclose
 
Julia Lostes
No Relationships to Disclose
 
Vladimir Galvao
No Relationships to Disclose
 
Guzman Alonso
No Relationships to Disclose
 
Honey Kumar Oberoi
No Relationships to Disclose
 
Irene Brana
Consulting or Advisory Role - Achilles Therapeutics; Boehringer Ingelheim; Cancer Expert Now; eTheRNA Immunotherapies; Merck Sharp & Dohme; Sanofi
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; MSD; Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); GlaxoSmithKline (Inst); Gliknik (Inst); Immutep (Inst); ISA Pharmaceuticals (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nanobiotix (Inst); Northern Biologics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Shattuck Labs (Inst); VCN Biosciences (Inst)
Travel, Accommodations, Expenses - MSD Oncology
 
Mafalda Oliveira
Honoraria - Eisai Europe; Gilead Sciences; MSD; Novartis; Pfizer; Roche; SeaGen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; ITeos Therapeutics; Relay Therapeutics; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Roche/Genentech (Inst); Seagen (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Eisai; Gilead Sciences; Pierre Fabre
 
Macarena González
Consulting or Advisory Role - Bayer; Ipsen
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Ipsen; Lilly; Lilly; Novartis; Pfizer; Pierre Fabre; Roche
 
Enriqueta Felip
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BerGenBio; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; F. Hoffmann LaRoche; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Sanofi; Takeda; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; F. Hoffmann LaRoche; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; PeerVoice; Pfizer; Sanofi; Takeda; Touch Oncology
Research Funding - Merck (Inst); Merck KGaA (Inst)
Other Relationship - GRIFOLS
 
Cristina Saura
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; MediTech; Novartis; Pfizer; Pharmalex; Philips Healthcare; Pierre Fabre; Pint Pharma; Puma Biotechnology; Roche; SeaGen; Synthon; Zymeworks
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Exeter Pharmaceuticals; Lilly; Pfizer; Pierre Fabre; Puma Biotechnology; Seagen
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (BMS) (Inst); CytomX Therapeutics (Inst); Daiichi Sakyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); InnoUp (Inst); Lilly (Inst); Macrogenics (Inst); Menarini (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Roche (Inst); Sanofi/Aventis (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai Europe; Novartis; Pfizer; Puma Biotechnology; Roche
 
Joan Carles
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZéneca; Bayer; Bristol-Myers Squibb; Johnson & Johnson/Janssen; MSD Oncology; Pfizer; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; Johnson & Johnson
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Blueprint Medicines (Inst); BN ImmunoTherapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Deciphera; Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen-Cilag International NV (Inst); Karyopharm Therapeutics (Inst); Laboratories Leurquin Mediolanum (Inst); Lilly (Inst); Medimmune (Inst); Millenium Pharamceuticals (Inst); Nanobiotix (Inst); Novartis Farmacéutica SA (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi Aventis GmbH (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS; Ipsen; Roche
 
Teresa Macarulla
Consulting or Advisory Role - Ability Pharma; Advance Medical; Amgen; Aptitude Health; AstraZeneca; Basilea; Baxter; BioLineRX; Celgene; Eisai; Ellipses Pharma; Esteve; Incyte; Ipsen; Janssen; Lilly; Medscape; MFAR, Marketing Farmacéutico & Investigación Clínica; MSD; Novocure; Paraxel; Prime Oncology; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Zymeworks
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Agios (Inst); Amc Medical Research (Inst); Amgen (Inst); Armo Biosciences (Inst); ASLAN Pharmaceuticals (Inst); ASTRAZENECA (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Beigene (Inst); BiolineRx (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (BMS) (Inst); Cantargia AB (Inst); Celgene (Inst); Eisai (Inst); ERYTECH Pharma (Inst); Fibrogen (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Incyte (Inst); Ipsen (Inst); Keralty Group (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Millennium (Inst); Nelum Corp. (Inst); Novartis (Inst); Novocure (Inst); OncoMed (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Roche (Inst); VCN Biosciences (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Incyte; Merck; Prime Oncology; Sanofi; SERVIER
 
Elena Garralda
Employment - Next Oncology
Consulting or Advisory Role - Alkermes; Anaveon; Boehringer Ingelheim; Ellipses Pharma; F-Star Therapeutics; Hengrui Therapeutics; Incyte; Janssen; MAB Discovery; Roche; Sanofi; Seagen; Thermo Fisher Scientific
Speakers' Bureau - Lilly; MSD; Novartis; Roche; Seagen; Thermo Fisher Scientific
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Janssen (Inst); Novartis (Inst); Roche (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Other Relationship - Adaptimmune (Inst); Affimed Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Catalym (Inst); Cyclacel (Inst); CytomX Therapeutics (Inst); Cytovation (Inst); F-Star Beta Limited (Inst); F. Hoffmann LaRoche (Inst); Genentech (Inst); Genmab (Inst); HiFiBiO Therapeutics (Inst); Hutchison MediPharma (Inst); Imcheck Therapeutics (Inst); Immunocore (Inst); Incyte (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Merck KGaA (Inst); Novartis (Inst); Peptomyc (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Replimune (Inst); Ribon Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); SQZ Biotech (Inst); Symphogen (Inst); T-Knife (Inst); Taiho Pharmaceutical (Inst)
 
Josep Tabernero
Stock and Other Ownership Interests - Oniria Therapeutics
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Boehringer Ingelheim; Cardiff Oncology; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; HalioDx; Hutchison MediPharma; Ikena Oncology; Inspirna; IQvia; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology; Scorpion Therapeutics; Seagen; Servier; Sotio; Taiho Pharmaceutical; Tessa Therapeutics; TheraMyc; Tolremo
Other Relationship - Imedex/HMP; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource
 
Omar Saavedra
No Relationships to Disclose